The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
-
Here .
-
Google has announced that it is launching AI Overviews and AI Mode (together with other Gemini-based services) in France. While traditional ... -
EC, here . "The Commission also takes note of Google's proposals on how it plans to apply the principles of the decision to AI O...
-
Reuters, here . Too little, too late?
-
S. Salop, here. From what I have seen, this "modern" economic analysis certainly moves beyond a narrow focus on price. It takes ...
-
Pax Silica is presented by the US State Department as its flagship initiative on AI and supply-chain security; the FT reports the EU, Ger...
-
ArsTechnica, here.
No comments:
Post a Comment